Area of research
Pulmonary and Respiratory Medicine · Computer Networks and Communications
Research interest
Research focused on Cystic fibrosis and Ivacaftor, with related work in Pseudomonas aeruginosa, Gastroenterology, Cystic fibrosis transmembrane conductance regulator. Notable publications include 'Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis', 'Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor', and 'Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results'.
Designing the GALAXY study: Partnering with the cystic fibrosis community to optimize assessment of gastrointestinal symptoms
Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial
Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study
Effects of an Antioxidant-enriched Multivitamin in Cystic Fibrosis. A Randomized, Controlled, Multicenter Clinical Trial
Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results
Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis
Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis
Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor
<i>Pseudomonas aeruginosa In Vitro</i> Phenotypes Distinguish Cystic Fibrosis Infection Stages and Outcomes
Multicenter Intestinal Current Measurements in Rectal Biopsies from CF and Non-CF Subjects to Monitor CFTR Function
Standard care versus protocol based therapy for new onset <i>Pseudomonas aeruginosa</i> in cystic fibrosis